Petrucci, Giovanna
 Distribuzione geografica
Continente #
EU - Europa 1.879
NA - Nord America 1.738
AS - Asia 1.639
SA - Sud America 374
AF - Africa 48
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 3
Totale 5.694
Nazione #
US - Stati Uniti d'America 1.679
SG - Singapore 775
DE - Germania 549
CN - Cina 458
IT - Italia 359
BR - Brasile 305
SE - Svezia 301
UA - Ucraina 131
GB - Regno Unito 105
FR - Francia 104
IE - Irlanda 82
VN - Vietnam 76
ID - Indonesia 65
IN - India 63
FI - Finlandia 58
RU - Federazione Russa 56
TR - Turchia 41
CA - Canada 35
AR - Argentina 28
BD - Bangladesh 28
BE - Belgio 25
HK - Hong Kong 24
CZ - Repubblica Ceca 21
KR - Corea 19
AT - Austria 17
IQ - Iraq 17
ES - Italia 16
NL - Olanda 16
EC - Ecuador 13
ZA - Sudafrica 13
IR - Iran 12
AU - Australia 11
JP - Giappone 10
PK - Pakistan 10
MX - Messico 9
PL - Polonia 9
SA - Arabia Saudita 9
CI - Costa d'Avorio 8
VE - Venezuela 7
PH - Filippine 6
CH - Svizzera 5
CL - Cile 5
EG - Egitto 5
BG - Bulgaria 4
BO - Bolivia 4
CO - Colombia 4
KE - Kenya 4
LT - Lituania 4
LV - Lettonia 4
NI - Nicaragua 4
NO - Norvegia 4
PY - Paraguay 4
AZ - Azerbaigian 3
ET - Etiopia 3
HN - Honduras 3
JO - Giordania 3
KZ - Kazakistan 3
MA - Marocco 3
MY - Malesia 3
NG - Nigeria 3
TN - Tunisia 3
UY - Uruguay 3
BY - Bielorussia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EU - Europa 2
IL - Israele 2
LB - Libano 2
NZ - Nuova Zelanda 2
SN - Senegal 2
TT - Trinidad e Tobago 2
YE - Yemen 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
BB - Barbados 1
CG - Congo 1
CR - Costa Rica 1
EE - Estonia 1
HU - Ungheria 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
LK - Sri Lanka 1
NP - Nepal 1
PA - Panama 1
PE - Perù 1
QA - Qatar 1
RO - Romania 1
RS - Serbia 1
TJ - Tagikistan 1
UZ - Uzbekistan 1
YT - Mayotte 1
Totale 5.694
Città #
Singapore 373
Chandler 289
Ashburn 223
Beijing 84
Rome 78
Dublin 76
San Mateo 74
Jacksonville 69
Milan 57
Nanjing 56
Cattolica 55
Jakarta 55
Ann Arbor 53
Munich 53
Hefei 51
Los Angeles 49
Wilmington 46
New York 37
Boston 35
Moscow 34
Dearborn 29
Frankfurt am Main 28
Ho Chi Minh City 27
São Paulo 26
Woodbridge 26
Dallas 25
Nürnberg 25
Hong Kong 24
Princeton 24
Houston 23
Bremen 20
Brno 20
Brussels 20
Hounslow 20
Nanchang 20
Hanoi 18
Izmir 18
Bareggio 17
Lawrence 17
Redwood City 17
Kent 16
Turku 16
Helsinki 15
Hyderabad 15
Seoul 15
Tianjin 15
Fairfield 14
Chicago 13
London 13
Redmond 13
Shenyang 13
Seattle 12
Hebei 11
Kunming 11
Verona 11
Buffalo 10
Nuremberg 10
Vienna 10
Augusta 9
Belo Horizonte 9
Busto Arsizio 9
Lancaster 9
Manchester 9
Stockholm 9
Tokyo 9
Abidjan 8
Dhaka 8
Guangzhou 8
Mountain View 8
Zhengzhou 8
Brooklyn 7
Bursa 7
Hangzhou 7
Jinan 7
Montreal 7
Paris 7
Phoenix 7
Santa Clara 7
Amsterdam 6
Ankara 6
Bexley 6
Düsseldorf 6
Johannesburg 6
Marseille 6
Shanghai 6
Toronto 6
Warsaw 6
Andover 5
Baghdad 5
Boardman 5
Catania 5
Chieti 5
Denver 5
Guayaquil 5
Istanbul 5
Jeddah 5
Leawood 5
Ottawa 5
Santo André 5
The Dalles 5
Totale 2.802
Nome #
Qualitative and quantitative modifications of von willebrand factor in patients with essential thrombocythemia and controlled platelet count 304
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 178
The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes 177
Obesity is associated with in vivo platelet activation and impaired responsiveness to once-daily, low-dose aspirin 177
Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. 164
Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors 158
Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma. 157
In vivo platelet activation and aspirin responsiveness in type 1 diabetes mellitus 155
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target 154
In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes 151
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 145
Abnormal megakaryopoiesis and platelet function in cyclooxygenase-2-deficient mice 144
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 140
Pseudo-acquired vWD in essential thrombocythemia: the role of platelets 136
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 136
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance 121
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy 109
Aspirin, stroke and drug-drug interactions 109
Aspirin inhibits cancer stem cells properties and growth of glioblastoma multiforme through Rb1 pathway modulation 106
Effects of low-dose rivaroxaban combined with low-dose aspirin versus low-dose aspirin alone on in vivo platelet activation, endothelial function and inflammation in type 2 diabetes patients with stable atherosclerotic disease: the RivAsa randomized, crossover study 105
Preoperative psychological characteristics affecting mid-term outcome after bariatric surgery: a follow-up study 105
Aspirin inhibits proliferation and promotes differentiation of neuroblastoma cells via p21Waf1 protein up-regulation and Rb1 pathway modulation. 101
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 97
Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma 95
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 94
Tumorigenic potential of olfactory bulb-derived human adult neural stem cells associates with activation of TERT and NOTCH1. 93
Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response 93
Effect of very long-term storage and multiple freeze and thaw cycles on 11-dehydro-thromboxane-B2 and 8-iso-prostaglandin F2α, levels in human urine samples by validated enzyme immunoassays 92
Role of Oxidative Stress in the Pathogenesis of Atherothrombotic Diseases 92
influence of local environment on the differentiation of neuronal stem cells engrafted onto the injured spinal cord 88
Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia 86
Role of Oxidative Stress in the Pathogenesis of Atherothrombotic Diseases 84
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance 83
Stability of urinary thromboxane A2 metabolites and adaptation of the extraction method to small urine volume 82
Stability of the thromboxane B2 biomarker of low-dose aspirin pharmacodynamics in human whole blood and in long-term stored serum samples 81
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial 77
Effect of low-dose and standard-dose aspirin on PGE2 biosynthesis among individuals with colorectal adenomas: A randomized clinical trial 76
Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation 75
Pathophysiology of Thrombosis in Peripheral Artery Disease 75
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 74
Mesenchymal differentiation of glioblastoma stem cells 72
Variability in the Responsiveness to Low-Dose Aspirin: Pharmacological and Disease-Related Mechanisms. 71
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target 71
Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation 70
Inhibition of telomerase in the endothelial cells disrupts tumor angiogenesis in glioblastoma xenografts 70
Establishing tumor cell lines from aggressive telomerase-positive chordomas of the skull base: Technical note 66
Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome 66
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial 64
Physiologically based modelling of the antiplatelet effect of aspirin: A tool to characterize drug responsiveness and inform precision dosing 64
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial 63
Personalized medicine, pharmacogenetics, and clopidogrel: unraveling variability of response 60
Prolonged fasting promotes systemic inflammation and platelet activation in humans: a medically supervised, water-only fasting and refeeding study 57
Pathophysiology of Thrombosis in Peripheral Artery Disease 57
Influence of local environment on the differentiation of neural stem cells engrafted onto the injured spinal cord 55
Physiologically based modelling of the antiplatelet effect of aspirin: A tool to characterize drug responsiveness and inform precision dosing 53
Mesenchymal differentiation of glioblastoma stem cells 51
Totale 5.779
Categoria #
all - tutte 24.338
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.338


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021179 0 0 0 0 0 13 35 11 35 13 51 21
2021/2022390 40 18 5 24 30 10 10 85 14 19 59 76
2022/2023808 105 116 69 118 61 89 26 70 100 18 22 14
2023/2024507 15 108 19 58 44 46 31 16 15 25 51 79
2024/20251.066 28 24 68 49 103 30 17 81 136 88 252 190
2025/20261.521 392 87 214 324 422 82 0 0 0 0 0 0
Totale 5.779